INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
INCYTE CORP
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$113.25+0.18 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $23.42B
- P/E (TTM)
- 16.0
- Dividend yield
- –
Incyte statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Services-Commercial Physical & Biological Research companies for comparison
Valuation
| Measure | Incyte | Industry median |
|---|---|---|
| Market Cap | $22.96B | $73.61M |
| Enterprise Value | $19.49B | $55.54M |
| PE Ratio | 16.00 | 25.83 |
| PS Ratio | 4.28 | 3.25 |
| PB Ratio | 4.08 | 3.13 |
| P/TBV Ratio | 4.18 | 8.30 |
| P/OCF Ratio | 15.13 | 15.81 |
Enterprise value
| Measure | Incyte | Industry median |
|---|---|---|
| EV / Sales | 3.64 | 2.79 |
| EV / EBITDA | 11.43 | 15.81 |
| EV / EBIT | 12.10 | 22.04 |
Income (trailing twelve months)
| Measure | Incyte | Industry median |
|---|---|---|
| Revenue | $5.36B | $24.74M |
| Gross Profit | $4.96B | $19.54M |
| Operating Income | $1.61B | -$55.64K |
| Pretax Income | $1.77B | $45.62K |
| Net Income | $1.43B | -$97.64K |
| EBITDA | $1.71B | -$29.48K |
| EPS (Diluted) | $7.08 | $0.00 |
Margins
| Measure | Incyte | Industry median |
|---|---|---|
| Gross Margin | 92.5% | 40.4% |
| Operating Margin | 30.0% | 0.94% |
| Pretax Margin | 33.1% | 2.64% |
| Profit Margin | 26.7% | 0.51% |
| EBITDA Margin | 31.8% | 3.48% |
Returns
| Measure | Incyte | Industry median |
|---|---|---|
| Return on Equity (ROE) | 30.8% | 0.45% |
| Return on Assets (ROA) | 21.9% | -3.47% |
| Return on Invested Capital (ROIC) | 66.9% | 2.85% |
| Return on Capital Employed (ROCE) | 27.5% | 2.03% |
Growth
| Measure | Incyte | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 21.5% | 4.26% |
| Net Income Growth (YoY) | 6631.4% | -0.74% |
| EPS Growth (YoY) | 2522.2% | 9.14% |
| Revenue Growth (3Y CAGR) | 14.8% | 2.15% |
| Revenue Growth (5Y CAGR) | 14.0% | 7.37% |
| EPS Growth (3Y CAGR) | 61.6% | 6.08% |
Balance sheet
| Measure | Incyte | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.46B | $5.43M |
| Net Cash (Debt) | $3.46B | $17.62K |
| Net Cash Per Share | $17.08 | $0.00 |
| Equity (Book Value) | $5.62B | $10.50M |
| Book Value Per Share | $27.74 | $0.60 |
| Tangible Book Value | $5.49B | -$78.36K |
| Working Capital | $3.99B | $2.78M |
Financial position
| Measure | Incyte | Industry median |
|---|---|---|
| Current Ratio | 3.68 | 1.26 |
| Quick Ratio | 3.03 | 0.65 |
| Interest Coverage | 689.26 | -0.23 |
Cash flow (trailing twelve months)
| Measure | Incyte | Industry median |
|---|---|---|
| Operating Cash Flow | $1.52B | $8.04K |
Efficiency
| Measure | Incyte | Industry median |
|---|---|---|
| Asset Turnover | 0.82 | 0.83 |
| Inventory Turnover | 4.49 | 13.10 |
| Revenue Per Employee | $1.89M | $216.23K |
| Profits Per Employee | $503.44K | -$1.99K |
| Employee Count | 2,844 | 115 |
Dividends and yields
| Measure | Incyte | Industry median |
|---|---|---|
| Earnings Yield | 6.24% | -1.29% |
Shares
| Measure | Incyte | Industry median |
|---|---|---|
| Shares Outstanding | 202,698,000 | 29,217,800 |
| Shares Change (YoY) | -0.91% | 0.84% |
| Shares Change (QoQ) | 0.75% | 0.00% |
| Float | 134,927,000 | 26,226,050 |
| Shares Held by Insiders | 33.4% | 4.85% |
| Shares Held by Institutions | 100.0% | 83.3% |
Taxes
| Measure | Incyte | Industry median |
|---|---|---|
| Income Tax | $342.08M | $1.36M |
| Effective Tax Rate | 19.3% | 23.6% |
Scores
| Measure | Incyte | Industry median |
|---|---|---|
| Graham Number | $66.48 | $16.51 |
| Graham Upside | -41.3% | -50.2% |
| Altman Z-Score | 10.23 | 2.64 |
| Piotroski F-Score | 8 | 5 |
| Beneish M-Score | -2.43 | -2.75 |
Calculated by StockData from Incyte's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.